BR112021006092A2 - composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados - Google Patents

composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados Download PDF

Info

Publication number
BR112021006092A2
BR112021006092A2 BR112021006092-8A BR112021006092A BR112021006092A2 BR 112021006092 A2 BR112021006092 A2 BR 112021006092A2 BR 112021006092 A BR112021006092 A BR 112021006092A BR 112021006092 A2 BR112021006092 A2 BR 112021006092A2
Authority
BR
Brazil
Prior art keywords
composition
poloxamer
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
BR112021006092-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Rajesh Manchanda
Snehal Khedkar
Richard A. Strong Jr.
Ashley Banks
Bradley Tait
Christopher Loose
Will MCLEAN
Original Assignee
Frequency Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics, Inc. filed Critical Frequency Therapeutics, Inc.
Publication of BR112021006092A2 publication Critical patent/BR112021006092A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021006092-8A 2018-10-02 2019-10-02 composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados BR112021006092A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739933P 2018-10-02 2018-10-02
US62/739,933 2018-10-02
PCT/US2019/054235 WO2020072601A1 (en) 2018-10-02 2019-10-02 Pharmaceutical compositions comprising otic therapeutic agents and related methods

Publications (1)

Publication Number Publication Date
BR112021006092A2 true BR112021006092A2 (pt) 2021-07-20

Family

ID=68296763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006092-8A BR112021006092A2 (pt) 2018-10-02 2019-10-02 composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados

Country Status (10)

Country Link
US (1) US20220192984A1 (https=)
EP (1) EP3860562A1 (https=)
JP (1) JP2022504265A (https=)
KR (1) KR20210084484A (https=)
CN (1) CN113164381A (https=)
BR (1) BR112021006092A2 (https=)
CA (1) CA3114113A1 (https=)
MX (1) MX2021003773A (https=)
TW (1) TW202034900A (https=)
WO (2) WO2020072602A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
JP2021533788A (ja) * 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法
US20220175776A1 (en) * 2019-04-08 2022-06-09 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
CN114085803B (zh) * 2020-08-24 2024-04-26 北京大学 建立具有再生特性的类器官培养体系
CN118203665A (zh) * 2020-10-14 2024-06-18 澳大利亚耳科学研究所股份有限公司 生成内耳毛细胞的方法
WO2022192079A1 (en) * 2021-03-08 2022-09-15 The Regents Of The University Of California Compounds for protection of noise-induced hearing-loss
AU2023390101A1 (en) * 2022-12-07 2025-06-19 Freedom Biosciences, Inc. Treatment or prevention of depressive disorders through combination therapy
CN120053473B (zh) * 2025-04-25 2025-07-18 山东大学 赖氨酸甲基转移酶dot1l抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US447475A (en) 1891-03-03 pomerof
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP1109563A4 (en) 1998-08-04 2009-07-22 Madash Llp AT THE END MODIFIED HYDROGELE WITH TEMPERATURE DEPENDENT FEATURES
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
US8188131B2 (en) 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
EP2606884A1 (en) 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
US9828344B2 (en) 2012-06-01 2017-11-28 LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT e.V. (FLI) Inhibitors of the notch signaling pathway and secretion for use in medicine
US20150209367A1 (en) 2012-09-07 2015-07-30 Massachusetts Eye & Ear Infirmary Treating Hearing Loss
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
EP2897942B1 (en) 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015531792A (ja) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 1,4−ベンゾジアゼピノン化合物のプロドラッグ
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
WO2014047392A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
CN103169649A (zh) * 2013-04-11 2013-06-26 中国人民解放军总医院 温度和离子双重敏感型原位凝胶鼻腔给药系统
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3189134A1 (en) * 2014-09-03 2017-07-12 The Brigham and Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US20170304369A1 (en) 2014-10-08 2017-10-26 Agency For Science, Technology And Research Methods of differentiating stem cells into liver cell lineages
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
US20180353875A1 (en) 2015-12-22 2018-12-13 Basf Se A process for purification of polyether block copolymers
US10201540B2 (en) * 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) * 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
CN109311878B (zh) 2016-06-27 2022-05-24 豪夫迈·罗氏有限公司 作为γ-分泌酶调节剂的三唑并吡啶类化合物
WO2018007331A1 (en) 2016-07-08 2018-01-11 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
WO2018011164A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives
AR109829A1 (es) 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
JP6956175B2 (ja) 2016-10-04 2021-11-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二環式ヘテロアリール誘導体
AR110122A1 (es) 2016-11-08 2019-02-27 Hoffmann La Roche Fenoxitriazoles
WO2018111926A2 (en) 2016-12-16 2018-06-21 Inception 3, Inc. Methods of treating cochlear synaptopathy
EP4252856A3 (en) 2016-12-20 2024-01-24 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
EP3562483B1 (en) 2016-12-20 2025-09-03 Oligomerix, Inc. Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
EP3601276A1 (en) 2017-03-24 2020-02-05 Novartis AG Isoxazole carboxamide compounds and uses thereof

Also Published As

Publication number Publication date
CN113164381A (zh) 2021-07-23
JP2022504265A (ja) 2022-01-13
WO2020072601A1 (en) 2020-04-09
WO2020072602A1 (en) 2020-04-09
CA3114113A1 (en) 2020-04-09
EP3860562A1 (en) 2021-08-11
KR20210084484A (ko) 2021-07-07
US20220192984A1 (en) 2022-06-23
TW202034900A (zh) 2020-10-01
MX2021003773A (es) 2021-07-16

Similar Documents

Publication Publication Date Title
BR112021006092A2 (pt) composições farmacêuticas que compreendem agentes terapêuticos óticos e métodos relacionados
US20220339154A1 (en) Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
ES2749082T3 (es) Nuevos enfoques terapéuticos para tratar la enfermedad de Parkinson
AU763435B2 (en) Methods for preventing/treating damage to sensory hair cells and cochlear neurons
US11162071B2 (en) Compositions and methods for generating hair cells by upregulating JAG-1
US20220160664A1 (en) Taz activators and wnt agonists for treating ear disorders
CN108348452A (zh) 用于局部递送5-氨基乙酰丙酸的亲水性凝胶
CA3136424A1 (en) Combination of chir99021 and valproic acid for treating hearing loss
US20150073008A1 (en) Topical Application of Vinca Alkaloids for the Treatment of Actinic Keratosis
US20200080055A1 (en) Compositions and methods for generating hair cells by upregulating pi3k
CN114174496A (zh) 用于通过抑制表观遗传靶标来产生毛细胞的组合物和方法
JP2022520671A (ja) 耳障害を治療するためのバルプロ酸化合物及びwnt作動薬
Bielefeld et al. Protection from impulse noise-induced hearing loss with novel Src-protein tyrosine kinase inhibitors
ES2974073T3 (es) Uso terapéutico del afatinib en el cáncer
US10537552B2 (en) Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers
CA2426521A1 (en) Treatment of sexual dysfunction using bombesin antagonist
WO2025255106A1 (en) Methods and compositions for enhancing drug delivery into the inner ear
TW202103691A (zh) 口內用藥物及其用於治療或延緩口腔潛在惡性病變的用途
JP2006213629A (ja) キノン体若しくはキノン体前駆体に起因する毒性抑制剤

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: FREQUENCY THERAPEUTICS, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements